Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
EXEL - Exelixis, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$51.78
DETAILS
HIGH:
$56.00
LOW:
$46.00
MEDIAN:
$52.00
CONSENSUS:
$51.78
DOWNSIDE:
9.84%
Stock News
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 8:00 a.m. PT on Tuesday, September 8 in Boston. Citi 2026 Biopharma Back to School Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Wednesday, September 9 in New York City. Morgan.
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Zanzalintinib + TECENTRIQ achieved overall survival benefit in mCRC, but missed the non-liver metastases subgroup endpoint; FDA PDUFA date set for December 3, 2026. Q2 2026 revenues rose to $628.7M, but future sales growth is uncertain and full-year guidance was cut to $2.500–$2.550B.
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civi
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis' favor. The appellate court upheld the District Court's decision that three patents covering.
Strong Sales, Earnings Send Exelixis Shares Higher
Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.
Allworth Financial LP Takes Position in Exelixis, Inc. $EXEL
Allworth Financial LP bought a new position in shares of Exelixis, Inc. (NASDAQ: EXEL) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,562 shares of the biotechnology company's stock, valued at approximately $575,000. A number of other
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Exelixis (EXEL) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Aug. 17, 2026
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)
Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
NEW YORK--(BUSINESS WIRE)--Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The revenue shortfall came alon.
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of EXEL shareholders.
Price Targets
BMO starts Exelixis at Market Perform into patent cliff
$54.00
(was $53.12)
BMO Capital
Leerink downgrades Exelixis to Market Perform following Q2 results
$52.00
(was $52.59)
Andrew Berens
·
Leerink Partners
Exelixis price target lowered to $52 from $56 at Truist
$52.00
(was $54.54)
Gregory Renza
·
Truist Financial
Exelixis (EXEL) Reiterated at Market Outperform by Citizens Amid Handa Patent Suit
$55.00
(was $53.03)
UBS
Exelixis price target raised to $53 from $50 at Morgan Stanley
$53.00
(was $54.99)
Sean Laaman
·
Morgan Stanley
Exelixis price target raised to $49 from $45 at Barclays
$49.00
(was $56.04)
Etzer Darout
·
Barclays
Exelixis price target raised to $49 from $40 at Wells Fargo
$49.00
(was $56.50)
Wells Fargo
Exelixis price target raised to $46 from $43 at RBC Capital
$46.00
(was $55.53)
RBC Capital
Exelixis price target raised to $52 from $43 at UBS
$52.00
(was $55.45)
Ashwani Verma
·
UBS
H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
$56.00
(was $53.96)
Robert Burns
·
H.C. Wainwright
Truist Securities Assumes Exelixis (EXEL) at Hold
$54.00
(was $52.87)
Gregory Renza
·
Truist Financial
Exelixis price target raised to $45 from $44 at Barclays
$45.00
(was $44.89)
Barclays
Exelixis price target raised to $54 from $52 at H.C. Wainwright
$54.00
(was $42.94)
H.C. Wainwright
Exelixis price target raised to $44 from $43 at Stifel
$44.00
(was $42.98)
Stifel Nicolaus
Exelixis price target raised to $44 from $41 at Barclays
$44.00
(was $42.59)
Etzer Darout
·
Barclays
Exelixis price target raised to $49 from $48 at Morgan Stanley
$49.00
(was $41.29)
Sean Laaman
·
Morgan Stanley
Exelixis price target raised to $51 from $49 at Truist
$51.00
(was $44.65)
Truist Financial
Exelixis price target raised to $52 from $49 at H.C. Wainwright
$52.00
(was $44.79)
Robert Burns
·
H.C. Wainwright
Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley
$48.00
(was $46.19)
Morgan Stanley
BofA Securities Downgrades Exelixis (EXEL) to Underperform
$41.00
(was $43.58)
UBS